logo
MYGN_logo
The acquisition strengthens Myriad Genetics’ portfolio of Women’s Health products, expanding access to personalized genetic tests during the reproductive stage of a women’s life and beyond. With SneakPeek, Myriad now serves women earlier in their pregnancy, providing data-driven genetic insights through their lifetime with the Prequel® non-invasive prenatal screen, Foresight® carrier screen, and MyRisk™ Hereditary Cancer Test with RiskScore® for all ancestries

Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has acquired Gateway Genomics, LLC, a personal genomics company and developer of consumer genetic tests including the No. 1 selling SneakPeek® Early Gender DNA Test. SneakPeek reveals a baby’s gender at six weeks into pregnancy -- the only at-home test to do so with 99% accuracy and the earliest method available

By Myriad Genetics, Inc.
Published - Nov 01, 2022, 09:14 AM ET
Last Updated - Jul 22, 2024, 08:16 AM EDT
  • $67.5 million tuck-in acquisition strengthens Myriad’s Women’s Healthportfolio of prenatal products
  • Fast-growing SneakPeek test has helped 750,000 parents learn baby’s gender from home – earliest method to date at 6 weeks into pregnancy
    • Article Source
    Quick Links
    Categories
    Our Offices
    • 10kInfo, Inc.
      13555 SE 36th St
      Bellevue, WA 98006
    • 10kInfo Data Solutions, Pvt Ltd.
      Claywork Create
      11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
      Bengaluru, Karnataka 560076
    4.2 12182024